ProCE Banner Activity

OPERA Subset: Effectiveness of LA CAB + RPV in Virologically Suppressed, Treatment-Experienced People Living With HIV, Stratified by BMI

Conference Coverage
Slideset

In a retrospective study of a subset from a large cohort of people living with HIV in the United States, LA CAB plus RPV was associated with a high level of virologic efficacy over 2 years, regardless of BMI.

Released: October 23, 2023

Share

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner

Supporters

Supported by educational grants from Gilead Sciences, Inc., Janssen Therapeutics, Division of Janssen Products, LP., Merck & Co., Inc., Rahway, NJ, USA, and ViiV Healthcare.

Gilead Sciences, Inc.

Janssen Therapeutics, Division of Janssen Products, LP

Merck & Co., Inc., Rahway, NJ, USA

ViiV Healthcare